HANSA BIOPHARMA

Conference Call Presentation

Interim report January – June 2023

Lund, July 20, 2023

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

HANSA BIOPHARMA

Solid commercial performance in Q2 and advancements across all four franchises

1 Advancing the EU launch

- ✓ Solid sales performance in Q2'23; Sales doubled vs. Q1'23
- ✓ Desensitization clinical guidelines in five countries and Eurotransplant program
- ✓ Provisional approval in Australia in both living and deceased donor

2 Accelerating science across all franchises

- ✓ 76 patients enrolled in US ConfIdeS phase 3 trial
- ✓ First patients treated in ANCA-associated vasculitis phase 2 trial and anti-GBM phase 3 trial
- ✓ Gene therapy collaboration with Genethon in Crigler-Najjar syndrome
- ✓ Enrollment completed in HNSA-5487 phase 1 trial

3 Total Q2 revenue: 36.7m; Hansa financed into 2025

- ✓ SEK 29.6m in product sales
- ✓ SEK 7.1m in revenue recognition from partnerships
- ✓ Cash position: SEK 1.1bn (Q2'23)
- ✓ Write-up of SEK 1.4bn in intangible assets related to Idefirix®; Will increase Shareholder Equity

Scaling Idefirix® globally as we transform the desensitization treatment landscape and advance a new way of transplanting patients

Key activity matrix

1 Build the foundation for Idefirix®

- ✓ Commercialize in early-launch countries
- ✓ Secure Market Access in key markets
- ✓ Ensure clinical readiness/KOL engagement
- ✓ Implement medical guidelines (ESOT and country specific guidelines)
- ✓ Increase awareness on unmet need
- ✓ Initiate post approval study in Europe
- ✓ Support patient and organ access

2 Expanding internationally

- Leverage experience to scale Idefirix in Europe
- Secure FDA approval and launch in the U.S.
- Geographical expansion beyond core markets
- Full marketing authorization in Europe

3 Potential label expansion

- Potentially expand into living donor transplantation
- Potentially expand into other solid organs

Commercial sales uptake

Eurotransplant pilot program set to transform desensitization and increase clinical experience with imlifidase

Acceptable Mismatch Priority Program

CURRENT
Acceptable Mismatch (AM) Program
Allocates organs to patients who are immunologically compromised because of current and/or historic HLA-sensitization

20 patients to be included in the Pilot program in rounds of five

NEW PILOT
Eurotransplant Desensitization Program
Imlifidase-eligible patients who are incompatible to a deceased donor

Inclusion criteria for new program

- No age limitation for patients
- Donor below 65 years
- A minimal waiting time of 3 years in the AM program
- Final transplant center CDC crossmatch must be negative
- Informed consent form for a follow-up data



ETKAS, Eurotransplant Kidney Allocation System
ESP, Eurotransplant senior programme
AM, acceptable mismatch
HLA, Human leukocyte antigen

Idefirix receives provisional approval in Australia

First market to approve use in transplants from both living and deceased donors

Australian kidney disease and transplantation statistics

~15,200 patients suffer from ESRD and receive dialysis

1,338 patients were waitlisted for a kidney transplant from deceased donors in 2021

857 kidney transplantations were carried out in 2021

~21% of patients waitlisted have a cPRA score of 95 or higher

76/24 deceased vs living donor transplantations

Full approval in Australia will require submission to the TGA of further safety and efficacy data from studies that are currently underway (e.g. long-term follow-up, Post Approval Study and U.S ConfIdeS study)

Kidney transplantation landscape in Australia



Sources:

1. ANZDATA. The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) collects information about people receiving dialysis or kidney transplant for end-stage kidney disease in Australia and New Zealand.
2. ANZDATA 2022 Annual Report #45; available at: https://www.anzdata.org.au/report/anzdata-45th-annual-report-2022-data-to-2021/

Potential to disrupt transplantation care in the U.S. with imlifidase

Complex allocation system with limited clinical innovation

25,000 annual kidney transplants

71% diseased donors

~90,000 patients on the waitlist

10-15% of waitlisted patients are highly sensitized

~6,000 highly sensitized patients with cPRA of 98% or above (hereof ~2,500 with cPRA of 99.9% and above)

U.S. ConfIdeS — Phase 3

- 76 patients screened and enrolled
- Plans to expand no of sites from currently 14 to 20 or more to accelerate randomization
- Randomization expected to be completed H2 2023, as previously guided

ConfIdeS phase 3 trial will further advance potential for imlifidase to address unmet need in desensitization

New investigator-initiated phase 2 study in ANCA-associated vasculitis

- a group of autoimmune diseases characterized by inflammation of blood vessels with very few treatment options today

Incidences

~3 in 100,000 annually across EU/US of which 8-36% are estimated to have ARDS due to pulmonary hemorrhage[1,2]

Standard of Care

- Current protocol is Immunosuppression and Intensive support care

Indication

- Causes damage to small blood vessels in the body resulting in inflammation and damage to organs, such as the kidneys, lungs etc.[3]
- Progress of the disease results in end stage kidney disease in 25 percent of patients[5]
- Most severe cases involving lungs lead to respiratory failure[4]
- Few treatment options today



Vasculitis means inflammation of blood vessels

The investigator-initiated trial (IIT) is sponsored by Charité Universitätsmedizin, Berlin

Study design

- Single arm, single center, phase 2 study with the primary objective to evaluate efficacy and safety on top of SoC
- 10 patients with severe ANCA-associated vasculitis and Acute Respiratory Distress Syndrome will be treated with imlifidase on top of SoC
- First patient treated Q2 2023
- Trial led by Dr. Adrian Schreiber and Dr. Philipp Enghard at Charité

1. Berti A, et al. Arthritis Rheum atol. 2017;69.
2. Rathmann J, et al. RMD Open. 2023;9:e002949.
3. Falk RJ, Jennette JC. The New England journal of medicine. 1988;318(25):1651-7.
4. Flossmann O, et al. Annals of the rheumatic diseases. 2011;70(3):488-94.
5. Booth AD, et al. American journal of kidney diseases. 2003;41(4):776-84.

Solid progress in our valuable pipeline of drug candidates across our franchises

U.S. ConfIdeS kidney tx

Phase 3

- 76 patients enrolled for randomization
- Plans to expand number of centers from currently 14 to 20 or more sites to accelerate randomization
- Randomization expected to be complete H2 2023

Anti-GBM disease

Phase 3

- 4/50 patients enrolled
- Open-label, randomized controlled study
- 50 patients to be treated with imlifidase and SoC or SoC, alone
- First patient treated in Q2

Guillain-Barré Syndrome (GBS)

Phase 2

- 30/30 patients enrolled
- Topline data expected H2 2023
- Full data following comparative efficacy analysis with the IGOS database expected 2024

Antibody Mediated Rejection (AMR)

Phase 2

- 30/30 patients enrolled
- Topline data showed statistical significance in rapidly reducing DSAs levels vs SoC
- Full data read-out expected H2 2023

ANCA associated vasculitis

Phase 2

- 10 patients with severe ANCA-associated vasculitis will be treated with imlifidase on top of SoC.
- Study is single center, single arm to evaluate efficacy and safety
- First patient treated Q2'23

- Patients enrolled
- Patients remaining

Broad clinical pipeline in transplantation and autoimmune diseases

Candidate/ Project	Indication	Research/ Preclinical	Phase 1	Phase 2	Phase 3	Marketing Authorization	Marketed	Next Anticipated Milestone
Imlifidase	EU: Kidney transplantation in highly sensitized patients[1,2]							EU: Additional agreements around reimbursement / Post approval study to be completed by 2025
	US: Kidney transplantation in highly sensitized patients[1,2]							Completion of randomization (64 patients) H2 2023
	Anti-GBM antibody disease[3]							Complete enrollment (50 patients)
	Antibody mediated rejection in kidney transplantation (AMR)							Full data read out H2 2023
	Guillain-Barré syndrome (GBS)							Topline data H2 2023 / Comparative efficacy analysis 2024
	ANCA-associated vasculitis[4]							Complete enrollment (10 patients)
	Pre-treatment ahead of gene therapy in Duchenne (Partnered with Sarepta)		Phase 1b					Initiate clinical study of imlifidase as pre-treatment in DMD 2023
	Pre-treatment ahead of gene therapy in Limb-Girdle (Partnered with Sarepta)							Preclinical research
	Pre-treatment ahead of gene therapy in Pompe disease (Partnered with AskBio)							Preclinical research
	Pre-treatment ahead of gene therapy in Crigler-Najjar syndrome (Partnered with Genethon)							Preclinical research
HNSA-5487	Lead molecule from second-generation IgG antibody cleaving enzymes (NiceR)							Completion of phase 1 (H2 2023)

Completed | Ongoing | Planned | Post approval study running in parallel with commercial launch

[1] Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)
[2] Lorant et al., American Journal of Transplantation and 03+04 studies (Jordan et al., New England Journal of Medicine)
[3] Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund, Sweden
[4] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charité Universitätsmedizin, Berlin, Germany

Q2 2023 Revenue amounted to SEK ~37m including SEK ~30m in product sales





Continued investments in commercialization and R&D activities

SG&A expenses (Q/Q)



R&D expenses (Q/Q)



Net loss (Q/Q)



SG&A expenses (H1/H1)



R&D expenses (H1/H1)



Net loss (H1/H1)



With current cash position and projected burn-rate, Hansa's operations are financed into 2025

Operating cash flow (Q/Q)



Operating cash flow (H1/H1)



Cash & short-term investments (Q/Q)



Number of employees (Q/Q)



Achieved and upcoming milestones

2023

H1 2023

- ✓ **U.S. ConfIdeS (Kidney tx) Phase 3:** Complete enrollment
- ✓ **Anti-GBM disease Phase 3:** First patient enrolled
- ✓ **GBS Phase 2:** Complete enrollment
- ✓ **ANCA-associated vasculitis Phase 2:** First patient enrolled
- ✓ **HNSA-5487 (Lead NiceR candidate):** Initiate Phase 1 study
- ✓ **Genethon Crigler-Najjar:** Initiate preclinical study with imlifidase prior to GNT-0003

H2 2023

- **U.S. ConfIdeS (Kidney tx) Phase 3:** Complete randomization
- **GBS Phase 2:** First data readout
- **AMR Phase 2:** Full data readout
- **Long-term follow-up (Kidney tx):** 5-year data readout
- **Sarepta DMD pre-treatment Phase 1b:** Commence clinical study
- **HNSA-5487 (Lead NiceR candidate):** Completion of Phase 1 study

2024

- **U.S. ConfIdeS (Kidney tx) Phase 3:** BLA submission
- **GBS Phase 2:** Outcome of the comparative efficacy analysis to IGOS data
- **Genethon Crigler-Najjar Phase 1/2:** Initiate clinical study with imlifidase prior to GNT-0003

Q&A

… at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives…

Visit our website
hansabiopharma.com



Contact our Investor Relations and Corporate Affairs team

Contact

Klaus Sindahl

VP, Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com

Stephanie Kenney

VP, Global Corporate Affairs

Mobile: +1 (484) 319 2802

E-mail: stephanie.kenney@hansabiopharma.com

Calendar and events

July 20, 2023	**Half-year Report for January-June 2023**
Aug 23, 2023	Carnegie non-deal road show, Stockholm
Aug 24, 2023	Erik Penser Company Day, Stockholm
Aug 31, 2023	HC Andersen – Life Science seminar (virtual)
Sept 11, 2023	HC Wainwright Annual Global Investment Conference, NYC
Sept 11, 2023	MorganStanley Global Healthcare Conference, NYC
Sept 14, 2023	Pareto Annual Healthcare Conference, Stockholm
Sept 14, 2023	Erik Penser Company Day, Malmö
Oct 2, 2023	Redeye: Autoimmune and inflammatory disease, Stockholm
Oct 5-6, 2023	Cowen US non-deal road show
Oct 12, 2023	Redeye: Afterwork, Malmö
Oct 19, 2023	**Interim Report for January-September 2023**
Nov 21, 2023	SEB Healthcare Seminar 2023, Stockholm
Nov 22, 2023	Ökonomisk Ugebrev Life Science event, Copenhagen


HANSA
BIOPHARMA